Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Receivables - Other: 2019-2021

  • Keros Therapeutics' Receivables - Other was N/A to $100,000 in Q2 2021 from the same period last year, while for Jun 2021 it was $100,000, marking a year-over-year change of. This contributed to the annual value of $922,000 for FY2019, which is N/A change from last year.
  • Latest data reveals that Keros Therapeutics reported Receivables - Other of $100,000 as of Q2 2021, which was down 87.58% from $805,000 recorded in Q1 2020.
  • In the past 5 years, Keros Therapeutics' Receivables - Other registered a high of $922,000 during Q4 2019, and its lowest value of $100,000 during Q2 2021.
  • For the 3-year period, Keros Therapeutics' Receivables - Other averaged around $609,000, with its median value being $805,000 (2020).